Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases

Christine Wolschkea Eray Goekkurtb Salah-Eddin Al-Batranc Dieter Kurt Hossfelda Jan Stoehlmacherb

a Medizinische Klinik II, Onkologie, Hämatologie und Knochenmarkstransplantation, Universitätsklinikum Hamburg-Eppendorf, b Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, c Medizinische Klinik II, Onkologie/Hämatologie, Krankenhaus Nordwest Frankfurt/M., Germany

Key Words
Gastric cancer · Pharmacogenetics · Chemotherapy

Summary
Background: Gastric cancer is often diagnosed in the metastatic stage, and only 10% of patients survive for as long as 2 years. Current chemotherapy regimens show significant treatment-related toxicities. It is crucial to identify the patients that will benefit most from certain chemotherapy regimens in order to avoid unnecessary side effects. Patients and Methods: 2 patients with advanced gastric cancer repeatedly received 5-FU/cisplatin combination chemotherapy. Genomic DNA was extracted from tumor tissue and mononuclear blood cells. Genotype analysis of genes of metabolizing and DNA repair enzymes was carried out using a PCR-RFLP technique. Direct sequencing was used to identify mutations of the gene dihydropyrimidine dehydrogenase (DPD).

Results: Prolonged survival of 51 and 29 months, respectively were observed in our 2 patients. Both patients were positive for genotypes of thymidylate synthase – the target enzyme of 5-FU – that are associated with improved drug response. DPD variants connected with increased toxicity were not observed. However, both patients also showed genotypes in cisplatin metabolizing enzymes which enhance the effect of the drug. Conclusion: Genotype analysis in drug metabolizing enzymes of 5-FU and cisplatin provide a possible explanation for extraordinary therapy effects observed in 2 patients with advanced gastric cancer.

Schlüsselwörter
Magenkarzinom · Pharmakogenetik · Chemotherapie

Zusammenfassung
Introduction

Gastric cancer is often diagnosed in advanced stages of the disease and is therefore associated with a poor prognosis. The median survival is as little as 6–8 months, and less than 10% of patients with metastatic disease survive for as long as 2 years [1]. Current treatment regimens – including epirubicin, methotrexat, platinum and 5-FU – are often highly toxic [2]. Recently, additional drugs such as irinotecan, taxanes and cetuximab have been introduced to palliative treatment of gastric cancer. The high toxicity and limited benefits of current chemotherapies for most gastric cancer patients require a careful selection of patients suitable for treatment. Currently, there are no efficient clinical, pathological or molecular markers to distinguish between responders and non-responders in relation to certain chemotherapy regimens used in gastric cancer. Pharmacogenetic analysis utilizes information on metabolic variations of administered chemotherapeutic drugs to predict clinical outcome. A combination of cisplatin and 5-FU is widely used in gastric cancer patients. Several functional genetic polymorphisms have been described for metabolizing enzymes of these substances such as thymidylate synthase (TS), glutathione S-transferase (GST) and excision cross complementing gene (ERCC) [3]. Here, we report on an extraordinary response to 5-FU/cisplatin combination chemotherapy in 2 gastric cancer patients. We further provide information on pharmacogenetic analysis demonstrating its potential as a predictor for clinical outcome in gastric cancer.

Case Reports

Clinical Observations

A 51-year-old female patient (patient A) was diagnosed with advanced gastric cancer in February 2001. Initial surgery revealed advanced peritoneal carcinomatosis, and parts of the omentum, the adnexes and a Krukenberg’s tumor were removed. A postoperative CT scan demonstrated advanced peritoneal carcinomatosis and a thickening of the stomach wall, but no further distant metastases. 6 weeks after surgery, a combination chemotherapy of 5-FU and cisplatin was initiated. The patient received 200 mg/m² leucovorin followed by 2000 mg/m² 5-FU once weekly and 50 mg/m² cisplatin every other week for 6 weeks (one cycle). Tumor assessment after 3 cycles of chemotherapy revealed that all tumor-related lesions had disappeared. Approximately 1 year after having been diagnosed, the patient once again showed tumor progression and a thickening of the stomach wall. The patient received 2 more cycles of chemotherapy followed by a Billroth II resection and remained disease-free for 10 months. In May 2004, the disease recurred in the remaining stomach and the abdominal cavity. The patient received 3 more cycles of 5-FU/cisplatin and did not show any disease progression until November 2004. At that point, the chemotherapy regimen was changed to 5-FU, leucovorin and mitomycin C. The patient last visited the hospital in May 2005, 51 months after the initial diagnosis of stomach cancer and peritoneal carcinomatosis. During the entire treatment, no major hematological or gastrointestinal toxicities were observed. The patient did not demonstrate any hepatic or renal failure.

Patient B, a 60-year-old female patient, was diagnosed with stomach cancer in December 2002 after having reported constantly increasing digestive problems and pains in the upper abdomen. Clinical examination revealed a 22 × 26 mm mass on the right abdominal wall. The stomach was removed (R2 resection) in an attempt to prevent gastric outlet obstruction, and examination of biopsies taken from the mass on the abdominal wall confirmed metastasized stomach cancer. 7 weeks after surgery, palliative chemotherapy with 5-FU/cisplatin as described above was started. After 2 cycles of combination chemotherapy, CT scans showed only minimal residual disease, and complete response was obtained after 3 cycles, followed by a disease-free interval of 23 months. 1 month prior to a scheduled follow-up visit at the outpatient clinic, patient B noticed significant weight loss and new abdominal pain. In February 2005, the disease progressed including retroperitoneal lymph node metastases, and the patient was put back on 5-FU/cisplatin combination chemotherapy. Upon last patient contact in May 2005, no disease progression was observed. In addition to the remarkable response to the treatment, patient B experienced severe side effects in the form of WHO grade-III diarrhea. The diarrhea was managed with saline infusions and oral loperamide. Since the patient had responded well to the first therapy cycle, we aimed to continue the chemotherapy regimen. Tumor response was evaluated according to the RECIST criteria. Toxicity was graded based on the WHO toxicity criteria. Both patients gave informed consent to perform genotype analysis. Patients A and B showed remarkable responses to 5-FU/cisplatin chemotherapy with prolonged time to progression and survival times of 51 months and 29 months, respectively.

Pathological Examination and Genotype Analysis

Patient A showed a poorly differentiated adenocarcinoma of the stomach. The tumor of patient B was moderately differentiated. For genotyping, DNA was extracted from both tumor sections and peripheral mononuclear cells. Genotyping was performed using a PCR based restriction fragment length polymorphism (RFLP) technique and direct sequencing [4]. Genetic polymorphisms were examined in the following genes involved in the metabolism of cisplatin and 5-FU: thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), glutathione S-transferase P1 (GSTP1) and excision repair cross complementing gene 1 (ERCC1). The genotypes are presented in table 1. Between tumor and host DNA, no genotype differences were observed.

Discussion

Both patients experienced prolonged survival and benefited significantly from repeated 5-FU/cisplatin combination chemotherapy. We analyzed functional genetic variations in the DNA sequence of metabolizing enzymes of 5-FU (TS-3', TS-5', DPD) and cisplatin (GSTP1-105, ERCC1-118). The TS-3' 1494del6 (-) variant and the TS-5' 2R and 3RC variants have been associated with decreased TS expression [6, 7]. Several reports link low TS expression levels to a favourable outcome of 5-FU based chemotherapy in gastrointestinal tumors including gastric cancer [8–10]. Patient A had TS genotypes (TS-3' and TS-5') associated with decreased TS levels, which may have enhanced the 5-FU action. Interestingly, no severe side effects were observed in this patient. High-grade hematological and gastrointestinal side effects have been described in patients with DPD deficiency [11]. The polymorphism in exon 14 of the DPD gene, that shows the highest frequency of known DPD polymorphisms and has been linked to
even fatal toxicity, was not identified in our patients [4]. The
dramatic side effects seen in DPD deficient patients are due to
accumulation of active metabolites of 5-FU, since DPD clears
more than 80% of 5-FU in the liver. However, patient B expe-
rienced grade-III diarrhea. Such an association between 5-FU
toxicity and TS genotype contrary to the effects on the tumor
has been reported before [12].

Although both patients harbored TS genotypes favoring
tumor response and increased toxicity, only patient B demonstr-
ated significant side effects. This reflects obvious limitations
of a pharmacogenetic approach focusing on key enzymes.
Functional variations in additional players such as methylen-
tetrahydrofolate reductase (MTHFR) or dUTP dinucleotido-
hydrolase (dUTPase) may have neutralized the 5-FU effect in
patient A but enhanced its power in patient B. Furthermore,
it has to be considered that responses seen in both patients
are the results of a combination chemotherapy of 5-FU and
cisplatin.

The detoxifying effect of GSTP1 on cisplatin is well estab-
lished [13]. The valine variant of a single nucleotide polymor-
phism (SNP) within exon 5 of the GSTP1 gene could be linked
to superior survival in colorectal cancer patients that received
5-FU/platinum chemotherapy [14]. The favorable GSTP1 vari-
ant was detected in its homozygous form in patient A. Patient
B was heterozygous for this polymorphism. In addition, both
patients demonstrated ERCC1 genotypes that have been
linked to impaired DNA repair capacity [15]. Taken together,
both patients demonstrated genotypes that enhance the plat-


\[
\begin{array}{|c|c|c|c|c|c|}
\hline
& TS-3' & TS-5' & TS-SNP & ERCC1-118 & GSTP1-105 & DPD \\
\hline
\text{Patient A} & -/- & 2R/3R & C & C/T & Val/Val & wt/wt \\
\text{Patient B} & +/- & 2R/3R & C & T/T & Ile/Val & wt/wt \\
\hline
\end{array}
\]


References

1 Janunger KG, Hafstrom L, Nygren P, Grimelius B; SBU-group. Swedish Council of Technology As-
essment in Health Care: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol
Meehan M: Randomized trial comparing epiru-
bicin, cisplatin, and fluorouracil versus fluorouracil,
donorubicin, and meothotrexate in advanced esoph-
3 Stoehlmacher J: Pharmacogenetics in gastrointesti-
4 van Kuilenburg AB, Muller EW, Haasjes J, Meins-
ma R, Zoetekouw L, Waterham HR, Barz F, Richel
DJ, van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidinase dehydrogenase
(DPD) deficiency after administration of 5-fluo-
rouracil: frequency of the common IVS14+1G>A
mutation causing DPD deficiency. Clin Cancer Res
2001;7:1149–1153.
5 Stochlmacher J, Park DJ, Zhang W, Yang D,
Groshen S, Zahedy S, Lenz HJ: A multivariate ana-
ysis of genomic polymorphisms: prediction of clinical
outcome to 5-FU/oxaliplatin combination chemother-
apy in refractory colorectal cancer. Br J Cancer
6 Mandola MV, Stochlmacher J, Zhang W, Groshen
S, Yu MC, Iqlab S, Lenz HJ, Ladner RD: A 6 bp
polymorphism in the thymidylate synthase gene
causes message instability and is associated with de-
creased intratumoral TS mRNA levels. Pharma-
7 Mandola MV, Stochlmacher J, Muller-Weeks S, Ce-
single nucleotide polymorphism within the 5’ tan-
dem repeat polymorphism of the thymidylate syn-
these gene abolishes USF-1 binding and alters tran-
8 Metzger R, Leichman CG, Danenberg KD, Danen-
berg PV, Lenz HJ, Hayashi K, Groshen S, Salonga
D, Cohen H, Laine L, Crookes P, Silberman H,
Baranda J, Konda B, Leichman L: ERCC1 mRNA
levels complement thymidylate synthase mRNA
levels in predicting response and survival for gastric
cancer patients receiving combination cisplatin and
cisplatin-induced DNA adducts by the nucleotide excision repair
pathway (ERCC1 genotype).
9 Leichman CG, Lenz HJ, Leichman L, Danenberg
K, Baranda J, Groshen S, Boswell W, Metzger R,
Tan M, Danenberg PV: Quantitation of intratu-
moreal thymidylate synthase expression predicts for
disseminated colorectal cancer response and resis-
tance to protracted-infusion fluorouracil and week-
10 Marcello E, Altes A, Del Rio E, Cesar A,
Menoyo A, Baiget M: Single nucleotide poly-
morphism in the 5’ tandem repeat sequence of
thymidylate synthase gene predicts for response to
fluorouracil based chemotherapy in advanced colo-
rectal cancer patients. Int J Cancer 2004;112:
733–737.
11 Van Kuilenburg AB, Meinsma R, Zoetekouw L,
Van Gennip AH: High prevalence of the IVS14 +
1G>A mutation in the dihydropyrimidinase dehydro-
genase gene of patients with severe 5-fluorouracil-
associated toxicity. Pharmacogenetics 2002;12:555–
558.
12 Pullarkat ST, Stoehlmacher J, Ghaideri V, Xiong YP,
Ingles SA, Sherrod A, Warren R, Tsao-Wei D,
Groshen S, Lenz HJ: Thymidylate synthase gene
polymorphism determines response and toxicity of
5-FU chemotherapy. Pharmacogenomics J 2001;1:
65–70.


17 Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, Boni C, Zuber E, Blattmann E: Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;(abstr 999).